Elutia Plans FDA Submission for NXT-41X This Quarter Following Successful Clinical Study
During its Q3 2026 management update, Elutia announced that its key GLP antimicrobial study has successfully met all predetermined endpoints. Building on this clinical milestone, CEO C. Mills confirmed that the company intends to submit its NXT-41X candidate to the FDA within the current quarter. The company is currently targeting a regulatory clearance date in the second quarter of 2027. This development marks a significant step forward in Elutia's pipeline as it moves toward commercialization readiness for its antimicrobial product.
Topics: biotechnology clinical trial results earnings call FDA submission